Radiopharm Theranostics Ltd (RAD)

Paul Hopper

Executive Chairman

Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors.

Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fifteen companies in the US, Australia and Asia.

Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Suda Pharmaceuticals. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances

Riccardo Canevari

Managing Director and Chief Executive Officer

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.

He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia. He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer.

He assessed Go To Market Models for each priority country and access to other markets. Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY. He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.

Professor David Mozley

Chief Medical Officer

David is a Professor of Nuclear Medicine with 30+ years in the nuclear medicine field.

He was most recently at Cornell University where he was Chief of Nuclear Medicine and single-site Principal Investigator for first-in-human pharmaceutical industry contracts from three different companies using novel radiopharmaceuticals as major endpoints. He was also the Physician Sponsor of 10 investigational new drug applications. At University Pennsylvania he was PI awarded more than $8M in NIH RO1 grants relating to radiopharmaceutical development. He has participated in over 60 clinical trials at Eli Lily and over 100 trials at Merck in novel radiopharmaceutical development.

Previously he was at Endocyte as Vice President of Imaging, coordinating efforts to take imaging based theranostics to market. He has co-authored more than 100 peer-reviewed publications mostly focused on radiopharmaceutical development and is widely renowned as a Board Certified physician.

Dr Thom Tulip

Chief Technology Officer

Thom has spent more than 25 years in the development and commercialisation of radiopharmaceuticals and imaging agents.

He has served in senior leadership roles at Navidea BioPharmaceuticals Inc, Alseres Pharmaceuticals, Lantheus Medical Imaging (LMI), Bristol Myers Squibb (BMS) and DuPont. He was a Board Member of the Academy of Molecular Imaging and Chairperson of its Institute for Molecular Technologies.

Dr Tulip was Chairperson of the Society of Nuclear Medicine Corporate Advisory Board and served as a Director of the Council of Radionuclides and Radiopharmaceuticals. He serves on the Board of Directors of the Medical Imaging Technology

Phillip Hains

Chief Financial Officer

Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’.

The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies (particularly biotechnology companies).

Phillip has over 25 years experience in providing businesses with accounting administration, compliance and general management services.

Alison Gartner

Project Manager

Alison has over 20 years experience as a biotech analyst and life science investor across ASX listed and private companies through her investment management roles at Asia Union Investments and life science fund BioScience Managers.

She is experienced in the establishment of VC and life science funds, and the portfolio management of assets from private start-ups through to FDA approvals, including involvement in private and public ASX capital raisings.

Ms Gartner is a Director of the National Foundation of Medical Research and Innovation, Project Manager at Chimeric Therapeutics and co-founder of Evidentli Pty Ltd.

Paul Hopper

Executive Chairman

Paul is the Founder of Radiopharm Theranostics. He has over 25 years experience in the biotech, healthcare & life sciences sectors.

Focussed on start-up and rapid growth companies, he has served as either Founder, Chairman, non-executive director, or CEO of more than fifteen companies in the US, Australia and Asia.

Previous and current Boards include Imugene, Chimeric Therapeutics, Viralytics, Prescient Therapeutics, Polynoma and Suda Pharmaceuticals. His experience covers extensive fund raising in US, Australia, Asia and Europe, and he has deep experience in corporate governance, risk and strategy. He also has many years experience in providing corporate advice and guidance, financial analysis and management of companies of differing sizes and financial circumstances

Riccardo Canevari

Managing Director and Chief Executive Officer

Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.

He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia. He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer.

He assessed Go To Market Models for each priority country and access to other markets. Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY. He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.

Ian Turner

Non-Executive Director

Ian is a highly experienced radiopharmaceutical and nuclear medicine supply and manufacturing expert with a distinguished C-level career across some of the leading corporations in the sector including CEO and President of Siemens PETNET Solutions from 2010-2012.

Prior to that role he was General Manager of ANSTO Radiopharmaceuticals in Sydney Australia, Australia's leading manufacturer of radioisotopes for the nuclear medicine sector. He was also Executive Director of PETNET Australia Pty Ltd. He spent a decade in various C-level roles at Varian Inc in Palo Alto and Melbourne.

Ian was also previously a Director of Coqui Pharmaceuticals until 2019, a company involved in the supply of radioisotopes in the US.

Dr Michael Baker

Non-Executive Director

Michael is currently CEO and MD of ASX listed Suda Pharmaceuticals which is developing technologies in the cell therapy and drug delivery fields.

Prior to Suda he was an Investment Manager with Australian life science fund, Bioscience Managers and a senior manager at Hexima Limited. He has a PhD in Biochemistry and was awarded the prestigious Nancy Millis award for the most outstanding thesis for the Faculty of Science, Technology and Engineering in 2010.

He was an Alexander von Humbolt Research Fellow at the University of Cologne. He has an MBA from Melbourne Business School.

Phillip Hains

Chief Financial Officer

Phillip is a Chartered Accountant operating a specialist public practice, ‘The CFO Solution’.

The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies (particularly biotechnology companies).

Phillip has over 25 years experience in providing businesses with accounting administration, compliance and general management services.

Hester Larkin

Non-Executive Director

Ms Larkin has a 30-year career spanning both pharmaceuticals and nuclear medicine across Europe, Middle East & Africa, including over 12 years experience in senior leadership roles in the industry. She brings a proven track record of leading successful product launches of proprietary pharmaceuticals and imaging agents in oncology, cardiology, neurology and HIV. Ms Larkin is currently MD of Hester Larkin Associates Consulting where she consults to diagnostic imaging, pharmaceutical and biotech companies on pre-clinical, clinical, EMA submission, EU medical advisory boards, EU manufacturing and commercial partnerships. She has held several Director and Trustee positions in the UK and Belgium and currently sits on the Board of 3 Charities. She was a business consultant at the Cardiac Imaging Department, Wellington Hospital when it launched the first Electron Beam CT (EBCT) centre. Ms Larkin was previously EMEA General Manager BMS Medical Imaging at Bristol-Myers Squibb and had a 19-year career at DuPont Pharmaceuticals holding several roles in European marketing, European Business development and General Management & VP positions. She was the first non-American female to be appointed as Managing Director & Vice President UK & Ireland for Dupont Pharmaceuticals. For 7 years Ms Larkin also chaired an Industry Working Group on Nuclear Medicine Awareness for ‘Nuclear Medicine Europe-the Industry Association,’ formerly AIPES. With a legal background Ms Larkin has experience in governance, risk, acquisitions, mergers, licensing & divestitures.